|
|
Post by mindovermatter on Jan 5, 2016 10:22:57 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants? They'd never do this. By terminating the partnership, Sanofi now has NO rights to Afrezza, freeing up Al and the board to agree to a buyout with literally anyone else. Sanofi is bye-bye. They have no chance of ever retaining any rights to Afrezza or any TS application now. I still think SNY wanted to buy it, but they wanted it cheap, far cheaper than Al was willing to sell for, so they starved the launch intentionally in the hopes that MNKD would go bankrupt and they could but it in liquidation. They never made an attempt at commercialization. Something tells me that with a new CEO slated to take over on the day that the partnership was terminated, that there is some plan in the works. People have speculated that there may be another partner waiting in the wings, but I'm not sure. I do think we'll find one but I'm not sure there's one now. This is most assuredly NOT a negative development. SNY was doing nothing to make Afrezza a success and was not providing liquidity to ensure MNKD's operations. We just cut A LOT of dead weight. New CEO, new partner, new future. Today is a good day. SNY hasn't put out a PR about them terminating the deal. It's only been MNKD. Could it be some are misinterpreting the PR and that Mannkind terminated the deal with SANOFI and that MANNKIND's wording of the pr only means they were kind enough to letting Sanofi to determine the date? I figure we'll find out the exact details this afternoon. |
|
|
|
Post by mindovermatter on Jan 5, 2016 10:11:38 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants?
|
|
|
|
Post by mindovermatter on Jan 5, 2016 9:53:29 GMT -5
Remember when things looked bleak when Drew Bledsoe got hurt and a young unknown named Tom Brady came in to the huddle?! Brady is a Michigan man. Desisto didn't go to Michigan. Mannkind needs a Michigan man. Get Harbaugh now! |
|
|
|
Post by mindovermatter on Jan 5, 2016 9:51:37 GMT -5
It was SNY who terminated from the statement "In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi's notice of termination, or July 4, 2016. This explains why Hakan is being kept on for "the transition". The question is, the transition to what? Mannkind is transitioning to a fast food truck business model. The trucks will be Fast Afrezza and will dispense them on street corners. Truck locations can be found via social media and a special app you can download. |
|
|
|
Post by mindovermatter on Jan 5, 2016 9:44:54 GMT -5
Al mentioned long ago he was approached by a Chinese pharma to partner. IIRC he was tempted but declined. He also mentioned there were smaller regional pharmas interested in Afrezza. Let's see if this path is taken.
It might be time for Mannkind to attack other countries than the United States to sell Afrezza. China, Saudi Arabia, Israel or any country on that list I posted a few weeks ago.
|
|
|
|
Post by mindovermatter on Jan 5, 2016 9:39:35 GMT -5
Game isn't over but but when your starting QB is taken out because he can't compete a pass and has thrown 7 ints and your RB is out because he broke his leg and your two starting wide outs are out due to concussions and your offensive line is comprised of 3rd stringers and you are down 49-0, things don't exactly look so great. MNKD is on life support right now. MNKD may be 9 and long, but they have a new QB. The Navy Midshipmen are my college FB team, 4 years ago, when the QB was injured a little known freshman quarterback came in to take over the game. Not only did he win, he stayed in as QB and crushed every record for running quarterbacks EVER. And we just hired a QB that has some positive experience with new technology! It is always darkest before the dawn. Football is a team sport and not about individual performance. Navy had a good year but look at the past records. Navy, historically, is a awful team. Mannkind is in trouble whether you want to believe it or not. The new CEO better hope they can get a partner to fill those french fuques shoes fast.  |
|
|
|
Post by mindovermatter on Jan 5, 2016 9:35:08 GMT -5
Can people now admit that Al made a huge mistake in partnering with Sanofi?
|
|
|
|
Post by mindovermatter on Jan 5, 2016 9:33:16 GMT -5
 It is now clear why Matt couldn't answer due to the black out period. He knew the deal was going to be terminated! The TASE listing had to have been done knowing that SNY was going to leave. Bottom line is never trust the French.
|
|
|
|
Post by mindovermatter on Jan 5, 2016 9:27:20 GMT -5
Game isn't over but but when your starting QB is taken out because he can't compete a pass and has thrown 7 ints and your RB is out because he broke his leg and your two starting wide outs are out due to concussions and your offensive line is comprised of 3rd stringers and you are down 49-0, things don't exactly look so great. MNKD is on life support right now. |
|
|
|
Post by mindovermatter on Jan 5, 2016 9:14:37 GMT -5
Many people have egg on their face with Sanofi saying bye bye to Mannkind. Adam and David were right this time. And so much for Sanofi's BRILLIANT MARKETING STRATEGY! LOL.
|
|
|
|
Post by mindovermatter on Jan 3, 2016 14:34:53 GMT -5
This is an interesting thread, and I thank Mnkdnewb for reminding us of cfield's excellent post earlier this year. I liked it then and I like it now, and nothing really has changed except an overdue change in leadership at MNKD after a less than inspiring offering on the TASE that did little other than feed the narrative that MNKD is desperate. This well intentioned but poorly timed faux pas by Mr. Edstrom fostered more confidence by the dark side and encouraged them to double down on their FUD, which seems to have been successful in getting many more weak hands to fold. Like others on this board, my wife and I saw "The Big Short" last night. It should be required for everyone who cares about the future of the nation. Anyone who views this true account of how Wall Street raped the country in 2008 without concluding that the market is still broken and badly needs reform might benefit from a soulful reflection on the true meanings of humanity, integrity and greed. The movie made it clear that what is happening with MNKD and other vulnerable stocks is entirely understandable in a market that learned no lessons in 2008 other than that being manipulative, arrogant and greedy can reap large rewards without penalty. The only satisfying part of the movie was seeing that those who predicted the crash and shorted the derivatives actually had some moral misgivings about profiting at the expense of average, hardworking people who lost their homes, jobs, savings and health because the church of greed was (and remains) the largest religious denomination in America. What we see in MNKD and the re-emergence of synthetic CDO's again trading on Wall Street is that the market remains so broken it no longer reflects reality. This partially explains why MNKD is trading at its current level. I applaud other longs who have done their due diligence and have stayed the course during these very dark times. Scion Investments, a company that did its due diligence and persisted despite weak-handed investors, massive ridicule, and efforts by Wall Street to hide the truth, ended up 489% after the crash. I remain convinced that long investors will also find ourselves with returns considerably better than what is reflected in today's share price. Good luck to you and sincere New Year's wishes for health, happiness, peace and justice. Chris C Don't forget Wall St had a very willing accomplice that set up the rules and regulation to allow it to do what it did. I'll let you guess who that entity was. |
|
|
|
Post by mindovermatter on Jan 3, 2016 13:39:18 GMT -5
I think that it's relevant that Duane mentioned improving shareholder value in his very first public statement after being hired. When I do my DD on other biotech/pharmaceutical development companies, they're issuing press releases that highlight positive test results from even preclinical studies. MannKind does none of that, so how are they suppose to attract BP or investors? Hopefully, Duane DeSisto will see to it that the public gets a look at much more than blithe statements like, "we have a plethora of riches". Years ago, MannKind published test results for multiple API and Alfred Mann, and other leaders from within the company, openly talked about the various API they want to develop. But for the past several years, MannKind has gone silent. It may have an over reaction by Mann to the shareholder lawsuit, but the time has come for MannKind Corporation to become more vocal about their technology and potential. I hope DeSisto puts an immediate end to all the silence. We must not expect much from Duane as will be on the job for only a few days. At this stage of the game, nothing can be worse for MNKD than a cheerleading CEO. We live in a swamp of plaintiff's lawyers whose primary prey are companies that can be snared using securities laws. These same lawyers will pass on biopharmas press releasing positive data for the promise of future value was created by the investors buying up the shares. My style of investing draws information from what companies say or do not say. It would be good to hear a reaffirmation from SNY. It would be very good if we hear about TS being ported to a new API. If we do not hear anything, it means the TS/API market has stalled. There is good reason to believe this since Afrezza has not been the American Pharaoh we all expected. We will know Mannkind is in serious trouble if Matt keeps interrupting and correcting Duane during the presentation as he did with Hakan.  |
|
|
|
Post by mindovermatter on Jan 3, 2016 9:51:20 GMT -5
I personally would like to see Matt leave, at this point I do not think he has much credibility left with shareholders, but I do not think it will happen any time soon. In any case this would be a god test on how much liberty of action DeSisto is given. To this day my biggest disappointment with Matt has been how disingenuously he has answered questions from investors, and more importantly how he has squandered the chance to rise capital under much better conditions. I guess there is still a chance, due to the fact that we know so little, that we might never see a secondary offering, but at this point I see this as unlikely. In any case the Hakan/Matt team left in place after approval by Mr. Mann has proven extremely inefficient at protecting shareholders interests over the last 17 months. If Al has truly handed over the reins to Desisto, don't be surprised if he cleans house starting with the CFO if he thinks Matt isn't up to the task to continue in that position. |
|
|
|
Post by mindovermatter on Dec 31, 2015 18:33:44 GMT -5
As 2015 comes to a close, I invite folks to speculate at what p/s will our favorite little company be trading on this date next year? Pick a number and please mention why you support that number, i.e. Afrezza approval in Europe or China, improved tier 2 insurance status, Technosphere application for second drug, or, if you think the worst, will MannKind even exist and be trading...All I want for 2016 is for Afrezza to finally find traction, get overly positive coverage, see Adam Fraudstain apologize for being wrong and see a few big TS deals get inked. Those should help lift the stock price. |
|
|
|
Post by mindovermatter on Dec 30, 2015 8:57:41 GMT -5
Here's an interesting list. A quick glance shows that Arab countries and people living on small Islands suffer the highest % and African countries the least. When I have more time, I'll have to google to see if there is any interpretation and analysis on this. www.allcountries.org/ranks/diabetes_prevalence_country_ranks.html |
|
It is now clear why Matt couldn't answer due to the black out period. He knew the deal was going to be terminated! The TASE listing had to have been done knowing that SNY was going to leave. Bottom line is never trust the French.
